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The identification and appropriate management of those at highest risk for life-threatening 
anaphylaxis remains a clinical enigma. The most widely used criteria for such patients were 
developed in a symposium convened by National Institute of Allergy and Infectious Disease/Food 
Allergy and Anaphylaxis Network. In this paper we review the current literature on the diagnosis of 
acute allergic reactions as well as atypical presentations that clinicians should recognize. Review of 
case series reveals significant variability in definition and approach to this common and potentially 
life-threatening condition. Series on fatal cases of anaphylaxis indicate that mucocutaneous signs 
and symptoms occur less frequently than in milder cases. Of biomarkers studied to aid in the work-
up of possible anaphylaxis, drawing blood during the initial six hours of an acute reaction for analysis 
of serum tryptase has been recommended in atypical cases. This can provide valuable information 
when a definitive diagnosis cannot be made by history and physical exam. [West J Emerg Med. 
2010; 11(5); 456-461.]
INTRODUCTION
Identifying “a textbook case” of anaphylaxis is something 
that most practicing emergency physicians are comfortable 
doing. When asked, treating physicians are likely to describe 
patients who presented with evidence of circulatory instability 
or collapse, mucosal edema and, in some cases, mechanical 
obstruction of the airway generally in the context of various 
initial cutaneous manifestations such as urticaria, angioedema, 
flushing or pruritus. In this paper, we will review a growing 
body of data indicating that there is more to making this 
diagnosis than generally is appreciated, and how diagnostic 
accuracy can be improved.
THE DIAGNOSIS OF ACUTE ALLERGIC REACTIONS
Currently, there is no universally accepted clinical 
definition of anaphylaxis. The diagnosis may be challenging 
as there is a large variability in presenting clinical signs and 
symptoms. In recognition of this, the National Institute of 
Allergy and Infectious Disease (NIAID) and the Food Allergy 
and Anaphylaxis Network (FAAN) convened a consensus 
meeting in July 2005 on anaphylaxis, which included 
representatives from 16 different organizations from North 
America, Europe, and Australia, to develop a clinically useful 
and universally accepted definition of anaphylaxis and provide 
guidance on the most appropriate management of anaphylaxis. 
These guidelines were published in 2006 and are currently 
widely accepted (Table 1). Despite a wide array of symptoms 
included in the clinical criteria, the consensus panel concluded 
that one in twenty patients is likely to be misdiagnosed. 
Clinicians are left with a considerable number of cases where 
there may be some doubt concerning the diagnosis.1
Studies on anaphylaxis report a range in incidence from 
3.2 to 58.9/100,000 cases annually.2-5 This wide range is likely 
a reflection of the variation in diagnostic criteria used and the 
paucity of a “gold standard”. Published studies reflect this 
variation with some strictly narrowing inclusion criteria to 
subjects with hemodynamic instability or mucocutaneous 
involvement while others use broader definitions making 
interpretation difficult.3,5-7 
The difficulties in standardization of research on 
anaphylaxis appears to also translate into clinical practice. A 
survey of 11 emergency medical systems (EMS) revealed a 
highly variable incidence of anaphylaxis ranging from 0.04% 
to 3.4% of all ambulance runs with the majority of systems 
reporting less than 1%. Among those EMS agencies reporting 
on the use of epinephrine autoinjectors, such injectors had 
been used in 0.16 to 31.1% of the cases.8 A study comparing 
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the recognition of acute allergic reactions caused by food 
exposures was highly variable. It was also notable that the 
proportion of patients referred to an allergist or provided with 
a prescription for self-injectable epinephrine on discharge 
from the ED was 12 % but highly variable9 (Figure 1).
In one retrospective study reviewing all ED records for a 
period of four months only one in every four patients who met 
criteria for anaphylaxis had been correctly diagnosed during 
their ED visit.6 The majority were diagnosed as having an 
acute allergic reaction. Based on the studies discussed above, 
there appears to be significant evidence of a need to 
standardize how anaphylaxis is diagnosed in the ED setting.
Beyond the complexities of identifying anaphylaxis, there 
are numerous reports of atypical presentations of acute allergic 
reactions that make this clinical diagnosis very challenging. 
This is evident in asthma, which is a disease related to 
anaphylaxis. In a study that reviewed the death records of 
individuals considered to have had an apparent fatal asthma 
attack, autopsy findings revealed that several of these patients 
had actually died from anaphylaxis.10 Acute symptoms of 
airway obstruction during an anaphylactic event have been 
misdiagnosed as being caused by a foreign body in the 
airway.11
Cardiac manifestations of anaphylaxis may mimic an 
acute coronary syndrome and acute anaphylaxis has been 
described to present with arrhythmias.12 This may be due to 
the physiologic stress of anaphylaxis in patients with pre-
existing coronary disease, but histamine has also been shown 
to directly induce coronary vasospasm in individuals with 
normal coronary arteries.13,14 This may occur as a part of the 
Tako-Tsubo or “broken heart” syndrome which is often 
attributed to abrupt physiologic stress.15,16 Exercise induced 
anaphylaxis may present as a syncopal event and should be 
considered in the differential diagnosis under appropriate 
circumstances.17
Vocal chord dysfunction is another cause of acute stridor 
presenting with a sensation of throat swelling. This condition 
can be challenging to differentiate clinically from anaphylaxis. 
When available, fiberoptic laryngoscopy during the attack will 
reveal no swelling but the characteristic intermittent adduction 
of the anterior vocal chords during inspiration.18-20 Other 
anxiety states such as panic attacks, globus hystericus and 
Munchausen stridor can also cause similar symptoms. 
The symptoms of acute attacks of hereditary angioedema 
can be identical to acute allergic reactions but usually do not 
respond to medications used to treat anaphylaxis. Other 
conditions known to cause anaphylaxis-like symptoms are 
flush syndromes such as carcinoid or disulfiram reactions, 
restaurant syndromes such as reactions to monosodium 
glutamate, sulfites or scombroid, autonomic epilepsy and 
vasomotor rhinitis. 
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Table 1. Clinical criteria for diagnosing anaphylaxis
Anaphylaxis is highly likely when any one of the following three 
criteria are fulfilled:
1. Acute onset of an illness (minutes to several hours) 
with involvement of the skin, mucosal tissue, or both (e.g. 
generalized hives, pruritus or flushing, swollen lips-tongue-
uvula)
AND AT LEAST ONE OF THE FOLLOWING
a. Respiratory compromise (e.g. dyspnea, wheeze-
bronchospasm, stridor, reduced PEF, hypoxemia)
b. Reduced BP or associated symptoms of end-
organ dysfunction (e.g. hypotonia [collapse], syncope, 
incontinence)
2. Two or more of the following that occur rapidly after exposure 
to a likely allergen for that patient (minutes to several hours):
a. Involvement of the skin-mucosal tissue (e.g. 
generalized hives, itch-flush, swollen lips-tongue-uvula)
b. Respiratory compromise (e.g. dyspnea, wheeze-
bronchospasm, stridor, reduced PEF, hypoxemia)
c. Reduced BP or associated symptoms (e.g. hypotonia 
[collapse], syncope, incontinence)
d. Persistent gastrointestinal symptoms (e.g. crampy 
abdominal pain, vomiting)
3. Reduced BP after exposure to known allergen for that patient 
(minutes to several hours):
a. Infants and children: low systolic BP (age specific) or 
greater than 30% decrease in systolic BP*
b. Adults: systolic BP of less than 90 mm Hg or greater 
than 30% decrease from that person’s baseline
PEF, Peak expiratory flow; BP, blood pressure.
*Low systolic blood pressure for children is defined as less than 
70 mm Hg from one month to one year, less than (70 mm Hg + [2 
times age]) from one to ten years, and less than 90 mm Hg from 
11 to 17 years.1
Figure 1. Percentage of patients discharged from the emergency 
department with documentation of instructions to avoid the 
offending allergen (A), prescription for self-injectable epinephrine 
(B), and referral to an allergist (C). Volume XI, no. 5  :  December 2010  458  Western Journal of Emergency Medicine
Considering all the above reported atypical presentations 
of anaphylaxis, it may be challenging in a significant number 
of cases to determine with any certainty the cause of a 
patient’s acute symptoms based on history and physical exam 
alone. This may be complicated even further if a detailed 
history is unobtainable or if a patient is not seen until after the 
acute symptoms have subsided.
LESSONS FROM SEVERE AND FATAL 
ANAPHYLAXIS
Fortunately, the majority of acute allergic reactions are 
mild and self-limited. Overall, mortality from anaphylaxis 
appears to be relatively rare, on the order of less than 1% of 
all cases.2-5,7 The highest published mortality rates are in the 
pre-hospital setting with a Norwegian study reporting a 
mortality rate of 7%.21 However, several of the large 
anaphylaxis case series do not report a single case 
fatality.2,4-5,7,9 This may be due to selection bias since many of 
the fatalities occur in the pre-hospital setting. Published case 
series of anaphylaxis fatalities suggest an incidence ranging 
from 0.3 to 0.8 per 1,000,000 with an increase in fatality rates 
among the elderly presumably due to comorbid conditions and 
iatrogenic drug exposures.22-24 When acute anaphylaxis results 
in death, the most common mechanism is circulatory collapse 
in cases of venom injections or iatrogenic reactions and 
respiratory failure in cases of food allergy.22,24 
Interestingly, the presence of cutaneous signs appears to 
be inveresly proportional to the severity of the anaphylactic 
event.24 In two studies of fatal anaphylaxis it was noted that 
less than 20% of the subjects had cutaneous findings.24,26 This 
stands in contrast to anaphylaxis studied in the office setting 
where the majority of patients had cutaneous signs.2,3,7,27 This 
may indicate that mucocutaneous signs take longer to develop 
than shock and respiratory distress and patients who live long 
enough to develop such signs are more likely to survive. Data 
from the pediatric population suggests that cutaneous signs 
also appear less frequently children than in adults, with about 
one in every five reported patients not having cutaneous 
findings.5 This paucity of cutaneous findings in the most 
severely affected is likely to contribute to misdiagnosis.
A prior history of asthma appears to be associated with 
poor outcomes. Almost all reported cases of fatal food related 
anaphylaxis occurred in individuals with a known history of 
asthma.16,23,28,29 That stated, the severity of previous attacks 
appears to be an unreliable prognostic tool as the majority of 
reported case fatalities have a history of only mild allergic 
reactions.16,23
In a review of 164 cases of all-cause fatal anaphylaxis in 
Great Britain, about half were noted to be iatrogenic.30 The 
most common iatrogenic causes reported were anesthetics and 
antibiotics, and fatal cases had a median time to cardiac arrest 
of only five minutes. Fatal venom injections had a median 
time to death of 15 minutes, ranging from 4-120 minutes, but 
fatal food allergy occurred slower with a median time to death 
of 30 minutes, ranging from six minutes to six hours. Also of 
note was that fatal food allergies occurred most commonly in 
children and younger individuals, whereas fatal iatrogenic 
anaphylaxis were seen more frequently among older 
individuals, likely due to higher exposure rates. In cases where 
death occurred several hours after the onset of symptoms, 
subjects commonly presented with mild symptoms, which 
then rapidly progressed during their period of observation. 
One case series noted that four patients had developed fatal 
circulatory collapse within minutes of being placed in an 
upright position and recommended keeping these patients 
laying flat.31
It is recommended that all individuals who have suffered 
an acute allergic reaction from exposures that might be 
encountered in nonmedical settings should receive instructions 
on how to avoid the precipitating allergen if it is known. 
Before discharge from the ED, patients should also be given a 
prescription for self-injectable epinephrine for use if 
anaphylaxis develops. Patients are also recommended to 
follow up with an allergist and should be given information on 
how to learn more about allergy from websites such as www.
foodallergy.org.
Despite the widespread use of self-injectable epinephrine, 
it must be stressed to patients that they must still avoid 
the offending allergen and that the epinephrine can not 
be relied on as a rescue medication. Auto-injectors have 
been associated with failures due to technical issues such 
as incorrect technique of administration or failure of the 
correctly administered dose to prevent fatality.16,30,32 Similiarly, 
when epinephrine has been given by health care providers, 
errors regarding appropriate dosaging and concentration of 
epinephrine used have been associated with poor patient 
outcomes. The use of pre-filled injectors by health care 
providers may avoid such errors.31,33
MARKERS OF ANAPHYLAXIS - TRYPTASE
A detailed clinical history and physical exam may not 
correctly identify all cases of anaphylaxis. Using laboratory 
markers as diagnostic adjuncts has been proposed and markers 
such as prostaglandin D2, carpoxypeptidase, CD63, interleukin 
4 and 6, CRP and tryptase have been evaluated for this 
purpose.34-36 Histamine released by degranulation of mast cells 
can be measured within five to ten minutes but only remains 
elevated for 30-60 min and therefore has a very limited value. 
To date, the marker most widely recommended is serum 
tryptase.
Tryptase is a neutral protease present in the secretory 
granules of all mast cells and to a lesser extent in basophiles.37 It 
is found in two isomers: α-tryptase, which is primarily elevated 
in those with mastocytosis; and β-tryptase, which is more 
commonly elevated in anaphylaxis.38 The most widely available 
assay measures total serum tryptase. One milliliter of serum is 
required for the assay and must be processed within three days 
if refrigerated.39 The peak level of serum tryptase in anaphylaxis 
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is one to two hours after the precipitating event and the serum 
half-life is approximately two hours.40 The ideal time to 
measure serum tryptase is considered within three hours but 
significant elevations can be found up to six hours or longer.41-43
In a study on anaphylaxis in children during a food 
challenge, an elevated tryptase had a sensitivity of 89% and 
specificity of 88%.44 In a review of 18 patients with confirmed 
anesthesia anaphylaxis, 12 had elevated serum tryptase 
levels.42 In the context of an acute event, an elevated tryptase 
level supports the diagnosis of anaphylaxis. Greater diagnostic 
accuracy however, appears to be associated with changes from 
a baseline level. In cases of experimental anaphylaxis in an 
antivenom trial a single serum tryptase value had a sensitivity 
of 36% and specificity of 93%, whereas a difference from 
baseline or delta tryptase level of 2.0 mcg/L had a sensitivity 
of 73% and specificity of 98%.45 This suggests that it may be 
useful to obtain a baseline tryptase value during a follow-up 
visit with the allergist.
USE OF TRYPTASE IN THE EMERGENCY 
DEPARTMENT
As discussed above, making the correct diagnosis in 
atypical cases can be challenging for the ED physician and 
using serum tryptase as a diagnostic adjunct should be 
considered. Current practice guidelines from the American 
Academy of Allergy, Asthma and Immunology and the 
American College of Allergy, Asthma and Immunology 
recommend that measuring serum tryptase may be helpful to 
confirm a diagnosis of anaphylaxis or rule out other causes. 
The guidelines note that proper timing when obtaining blood 
for tryptase measurement is essential and should be performed 
within six hours.46 The United Kingdom Resuscitation Council 
guidelines on anaphylaxis also recommend using serum 
tryptase during the acute attack to confirm the diagnosis 47
Only two studies have been identified where tryptase was 
measured specifically in ED patients with acute reactions. A 
study of patients with confirmed anaphylaxis where serum 
tryptase was measured within six hours from onset of 
symptoms and compared to baseline tryptase levels one month 
later revealed a sensitivity of 94% and specificity 92%.48 In 
another study where tryptase was measured in 96 ED patients 
with anaphylaxis, beta-tryptase was detectable in just 23 
patients and only 13 had elevated total tryptase levels. These 
results should be interpreted with caution as the study 
included patients who presented greater than 12 hours from 
the onset of symptoms. Applying current guidelines, only a 
minority of subjects met criteria for anaphylaxis.49
Currently, in most centers, serum tryptase levels are not 
available as a STAT study which may be a disincentive to 
those in the acute care setting. That stated, serum tryptase 
levels can help identify the cause of an atypical acute reaction 
of unknown etiology and is recommended as a diagnostic 
adjunct in cases of doubt. The significance of an individual 
patient’s elevated value should be determined by an allergist 
and ideally compared to a baseline value at a follow up visit. 
The patient’s ED visit is however the most opportune time 
to draw blood for tryptase analysis, and this may provide the 
follow-up physician with useful information.
CONCLUSION
Reviewing current data on anaphylaxis, it is evident 
that the definition and standardization of this diagnosis has 
been variable. Maintaining a high index of suspicion in 
patients presenting with atypical signs and symptoms can 
improve diagnostic accuracy and avoid poor outcomes due to 
misdiagnosis. Emergency physicians should be familiar with 
the currently recommended diagnostic criteria and the option 
to measure serum tryptase levels within the first six hours of 
presentation as a diagnostic adjunct in atypical cases.
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